A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence
Atsushi Oyama(Okayama University), Hiroyuki Okada(Harvard University), Nozomu Wada(Okayama University), Ryuichi Yoshida(Okayama University), Akinobu Takaki(Okayama University), Mari Yoshida(Okayama University Hospital), Hidenori Shiraha(Kawasaki Medical School), Chisato Arimori(Okayama University Hospital), Tetsuya Yasunaka(Okayama University), Hideki Onishi(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Kosei Takagi(Okayama Shoka University), Fusao Ikeda(Okayama University), Takashi Kuise(Okayama Red Cross General Hospital), Takahito Yagi(Okayama University), Takuya Adachi(Okayama University), Yasuhito Takeuchi(Okayama University), Shinichiro Nakamura(Himeji Red Cross Hospital), Yuzo Umeda(Okayama University)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size
|The American Journal of Gastroenterology|2006|165